Email ID
Password
Home - Comment
JOB OF THE WEEK Promote your vacancy here
Just as it appeared that the private investment market was beginning to rebound after last year's drought, the monthly total secured by private companies slumped once more in February, a Scrip analysis has found. Ten privately held pharmaceutical ...
The fall in Genzyme 's share price made it an obvious target. The Massachusetts based biotech company's value had been hammered by its inability to deal with several contamination issues in the manufacture of its rare genetic disease ...
Private investments began 2010 in a much more positive fashion than at the start of 2009, but were still down on the strong finish to last year, a Scrip analysis has found. A total of 15 companies raised $286.7 million, 17% lower than December. ...
Bulgaria's government is close to implementing major changes to its national healthcare services to tackle its perpetual budget deficit. The changes may involve the closure of up to 150 inefficient hospitals this year, including 21 which are ...
 
Logos are said to be an important part of an organisation's branding. Really good logos contribute to an organisation's visibility, credibility and memorability, so say branding experts. The logo of the most famous of the medicines regulators, the ...
Emerging markets are a popular topic at the moment, with pharma firms seeking sales growth outside the mature and slowing markets of the west. There are some companies with a long history of participating in these markets, such as AstraZeneca, which ...
GlaxoSmithKline will enter unknown regulatory waters when it eventually comes to seek approval of its paediatric malaria vaccine, RTS,S, the most advanced in development for this disease. The parasite kills more than 800,000 people every year, the ...
The European pharmaceutical industry association, EFPIA , should be commended on its Swedish pilot for a mass serialisation scheme designed to reduce the risk of counterfeit medicines in the legal supply chain (scripnews.com, October 20th, 2009). To ...
 
Trust and respect seem to be in short supply these days, at least where certain sectors of society are concerned. At international level, the banking industry is under a dark cloud of public opprobrium for its role in the global financial crisis. In ...
The fact that many poor countries globally suffer as a result of the lack of access to life-saving medicines is lamentable. Whereas certain mechanisms have been devised with the aim of addressing this issue, the move towards assuring worldwide ...
It has been a bad week for anticancer drug development, with two late-stage projects coming to grief and a third being shelved. First came news that Danish company Genmab ’s head and neck cancer product, zalutumumab (HuMax-EGFr), had failed to meet ...
Following the latest round of pharma mergers and as a long-time participant in this industry-shaping activity, I was recently asked: “Do mergers hurt innovation?” The biggest “hurt” occurs when the R&D talent of the smaller company walks away, ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36